IL17A and metabolic disease: Although our study was not sufficiently powered to substantiate the previously reported metabolic disease-associated Th17 profile of MAIT cells, 5-A-RU could offer a technical advantage, in future studies, due to the fact that it induces significantly lower “background” IL-17-production in MAIT cells from healthy controls as compared to PMA/ionomycin treatment (p = 0.001, Wilcoxon matched-pairs signed rank test; data from Figures 3A,B).